Istanbul, Turkey (PRWEB) June 4, 2008
Bayer HealthCare announced today the recipients of the 2008 International Hemophilia Nursing Fellowship, a program established by the World Federation of Hemophilia to improve the treatment of hemophilia in developing countries through state-of-the-art education and training. Bayer, the sole sponsor of the program, supports the fellowship as part of its commitment to people around the world living with hemophilia.
Bayer's support of the International Hemophilia Nursing Fellowship Program directly improves treatment for some of the world's most difficult-to-reach patients. Currently, approximately 70 percent of undiagnosed and undertreated people with hemophilia live in developing countries, where hemophilia-trained nurses and healthcare professionals are in short supply.
"Effective hemophilia treatment begins with providing medical professionals access to the training and tools they need to learn current treatment practices," said Mark Skinner, president, WFH. "The hands-on experience nursing professionals receive through this international fellowship goes a long way toward improving hemophilia care in developing countries. By advancing nursing in these countries, the WFH is helping to improve the lives and long-term health of people with hemophilia and their communities. This wouldn't be possible without Bayer's generous support."
This year's fellowship winners are:
- Nombuyekezo Felicity Ncapai from South Africa, to be trained in Oxford, UK
- Cecilia Melendez de Soriano from El Salvador, to be trained in Houston, USA
- Zahra Sha'bani from Iran, to be trained in London, UK
- Margaret Wisdom-Phipps from Jamaica, to be trained in Los Angeles, USA
Nurses are critical members of the hemophilia treatment team, and through this fellowship, they travel to one of 31 International Hemophilia Training Centers (IHTCs), where they receive clinical and laboratory training. Since the fellowship's inception in 2005, award recipients have trained at facilities across the globe, from Spain and Thailand to Australia and Argentina.
"I am grateful for the opportunity to learn new skills to help my patients and their families," said Zahra Sha'bani from Tehran, Iran. "The opportunity to share the experience I gained from working alongside leading international nurses and doctors will be a tremendous asset to my local hemophilia community."
Bayer has also demonstrated its commitment to the global hemophilia community by donating product, both directly and through the WFH to address humanitarian needs; funding hemophilia research and education through the Bayer Hemophilia Awards Program; and supporting leadership training programs -- such as Step Up Reach Out and the National Youth Leadership Institute -- to help develop the next generation of advocates within the bleeding disorders community.
"Bayer once again is proud to support this year's winners of the International Hemophilia Nursing Fellowship, but the real winners are the people with hemophilia who will receive the benefit of that training," said Michael E. Mathews, general manager, hemophilia, and vice president of marketing, specialty medicine, Bayer HealthCare. "Bayer strongly believes that the knowledge and skills of the hemophilia treatment team is a critical component of the overall standard of care. As such, Bayer is committed to providing the medical communities in developing countries with the training and tools needed to help those with hemophilia live the lives they choose."
About Hemophilia A
Hemophilia A, also known as factor VIII deficiency or classic hemophilia, is largely an inherited bleeding disorder in which one of the proteins needed to form blood clots in the body is missing or reduced. Hemophilia A is the most common type of hemophilia and is characterized by prolonged or spontaneous bleeding, especially into the muscles, joints, or internal organs. Approximately 400,000 people around the world have hemophilia A.
About Bayer HealthCare LLC
Bayer HealthCare LLC is an affiliate of Bayer HealthCare AG. Bayer HealthCare AG is one of the world's leading, innovative companies in the healthcare and medical products industry, and based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Diabetes Care, and Pharmaceuticals divisions. The Pharmaceuticals division comprises the following business units: Women's Healthcare, Diagnostic Imaging, General Medicine, and Specialty Medicine. Bayer HealthCare's aim is to discover and manufacture products that will improve human and animal health worldwide. The products enhance well-being and quality of life by diagnosing, preventing and treating diseases.
This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our annual and interim reports filed with the Frankfurt Stock Exchange. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
# # #